Anixa Biosciences, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-08$5.22 RISE2026-03-30$2.50 PEAK2026-04-22$3.14 135d | -52.1% 112d | Missed | Missed | — | — | +25.6% 23d | Missed |
DROP2025-10-09$4.92 RISE2025-11-04$3.97 PEAK2025-12-08$5.22 60d | -19.3% 26d | Missed | Missed | — | — | +31.5% 34d | Missed |
DROP2025-06-16$3.75 RISE2025-08-20$2.92 PEAK2025-10-09$4.92 115d | -22.1% 65d | Missed | Missed | — | — | +68.5% 50d | Missed |
DROP2025-03-24$3.20 RISE2025-05-27$2.50 PEAK2025-06-16$3.75 84d | -21.9% 64d | Missed | Missed | — | — | +50.0% 20d | Missed |
DROP2025-03-24$3.20 RISE2025-05-23$2.50 PEAK2025-06-16$3.75 84d | -21.9% 60d | Missed | Missed | — | — | +50.0% 24d | Missed |
DROP2024-12-03$3.32 RISE2025-04-08$2.38 PEAK2025-06-16$3.75 195d | -28.3% 126d | Missed | Missed | — | — | +57.6% 69d | Missed |
DROP2024-10-28$3.97 RISE2025-01-14$2.13 PEAK2025-03-24$3.20 147d | -46.3% 78d | Missed | Missed | — | — | +50.2% 69d | Missed |
DROP2024-03-20$3.73 RISE2024-07-09$2.21 PEAK2024-09-20$3.48 184d | -40.8% 111d | Missed | Missed | — | — | +57.5% 73d | Missed |
DROP2024-02-20$3.86 RISE2024-06-28$2.21 PEAK2024-09-20$3.48 213d | -42.7% 129d | Missed | Missed | — | — | +57.5% 84d | Missed |
DROP2024-01-16$5.02 RISE2024-03-14$3.08 PEAK2024-03-20$3.73 64d | -38.6% 58d | Missed | Missed | — | — | +21.1% 6d | Missed |
DROP2024-01-16$5.02 RISE2024-03-12$3.08 PEAK2024-03-20$3.73 64d | -38.6% 56d | Missed | Missed | — | — | +21.1% 8d | Missed |
DROP2023-07-17$3.87 RISE2023-11-08$2.85 PEAK2024-01-16$5.02 183d | -26.4% 114d | Missed | Missed | — | — | +76.1% 69d | Missed |
DROP2023-07-17$3.87 RISE2023-10-02$3.02 PEAK2023-12-11$4.19 147d | -22.0% 77d | Missed | Missed | — | — | +38.7% 70d | Missed |
DROP2023-04-14$5.97 RISE2023-07-07$2.97 PEAK2023-07-17$3.87 94d | -50.3% 84d | Missed | Missed | — | — | +30.3% 10d | Missed |
DROP2022-10-26$5.81 RISE2023-02-23$3.86 PEAK2023-04-14$5.97 170d | -33.6% 120d | Missed | Missed | — | — | +54.7% 50d | Missed |
1–15 / 29 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.
Anixa Biosciences, Inc. announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone...
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, May 2, at 7pm ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.
ORLANDO, FL / ACCESS Newswire / May 1, 2026 / RedChip Companies will air interviews with Anixia Biosciences, Inc. and OwlTing Group , the operating brand of OBOOK Holdings Inc., on the RedChip Small...
Anixa Biosciences Inc: Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology...
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI)
SAN JOSE - Anixa Biosciences, Inc. , a biotechnology company focused on the treatment and prevention of cancer, announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene...
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a
ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Biotech Resurgence: Platforms and ...
Anixa Biosciences (NASDAQ:ANIX) CEO Dr. Amit Kumar outlined the company’s strategy for advancing two clinical-stage oncology programs while maintaining what he described as a “very modest” cash burn during a Water Tower Research conference session moderated by Robert Sassoon, Managing Director of He
Anixa Biosciences (NASDAQ:ANIX) CEO Dr. Amit Kumar outlined the company’s strategy for advancing two clinical-stage oncology programs while maintaining what he described as a “very modest” cash burn during a Water Tower Research conference session moderated by Robert Sassoon, Managing Director of He
ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual investor conference, Biotech Resurgence: Platforms ...
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today's Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming Water Tower Research (WTR) Insights Conference on April 14, 2026, at 12:30 pm ET.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was recently featured in an interview on the Smart Money Circle program hosted by Adam Sarhan.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with Cytovance Biologics (www.cytovance.com), a leading full-service contract development and manufacturing organization ("CDMO") specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2 clinical trial of its b
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participantsSAN JOSE, Calif., April 1, 2026 /PRNewswire/ --
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held April 10 – 13, 2026, in San Juan, Puerto R
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANIX | -14.01% | -8.78% | -13.46% | +5.06% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -16.98% | -3.07% | -10.02% | -7.63% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 159.0K | $410.32K | 0.00% | Unchanged | 2026-03-31 |
| RenTech | quant | 61.2K | $157.83K | 0.00% | Added+13.6% | 2026-03-31 |
| Citadel | multi-strat | 17.3K | $44.57K | 0.00% | Trimmed-44.4% | 2026-03-31 |
| TwoSigma | quant | 14.5K | $37.39K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-10upcoming | -0.10 | — | — |
| 2026-03-09 | -0.09 | -0.08 | +11.11% |
| 2026-01-12 | -0.09 | -0.09 | — |
| 2025-09-10 | -0.10 | -0.07 | +30.00% |
| 2025-05-28 | -0.10 | -0.09 | +10.00% |
| 2025-03-11 | -0.10 | -0.10 | — |
| 2025-01-10 | -0.11 | -0.09 | +18.18% |
| 2024-09-06 | -0.11 | -0.10 | +9.09% |
| 2024-06-04 | -0.11 | -0.10 | +9.09% |
| 2024-03-12 | -0.09 | -0.10 | -11.11% |
| 2024-01-16 | -0.09 | -0.09 | — |
| 2023-09-06 | -0.09 | -0.08 | +11.11% |
| 2023-06-14 | -0.11 | -0.07 | +39.13% |
| 2023-03-17 | -0.16 | -0.08 | +50.00% |
| 2023-01-04 | -0.11 | -0.12 | -9.09% |
| 2022-09-09 | -0.13 | -0.09 | +30.77% |